Cambridge Healthtech Institute’s 8th Annual

Antibodies Against Membrane Protein Targets – Part 1

Discovery and Development of Biologics Against GPCR, Ion Channel, and Transporter Targets

September 16-17, 2020

 

As the pharmaceutical and biotech industries increasingly shift attention to biologics, much more attention is being paid to the prospect of developing membrane-bound targets for biotherapeutics. For the large GPCR and ion channel target classes, biologics offer improved selectivity, an alternative for targets with known function that have not been amenable to small molecule drugs, and the potential for using antibodies for the targeted delivery of therapeutics. However, for the field to advance, fundamental challenges in optimizing antigen quality and presentation, discovery methodologies, protein engineering and target identification must be resolved. This two-part meeting provides a forum in which discovery biologists and protein engineers can come together to discuss next generation strategies and technologies that will allow biologic drugs for these target families to advance into the clinic and beyond.

Preliminary Agenda

GPCR TARGETS

Platforms for Production of Functional mAbs for Membrane Proteins

Eric Grazzini, PhD, Team Leader, Rapid Protein Production, National Research Council of Canada

Function-Based High-Throughput Screening for Antibody Antagonists and Agonists against G Protein-Coupled Receptors

Meiyun Zhang, PhD, Principal Scientist, Antibody Discovery, Amgen, China

KEYNOTE PRESENTATION: New GPCR Signaling Circuitries: Opportunities for Novel Precision and Immune Therapies

J. Silvio Gutkind, PhD, Professor, Pharmacology, Moores Cancer Center, University of California, San Diego

Nanobodies Targeting and Modulating GPCR Function

Martine Smit, PhD, Professor, Target and Systems Biochemistry, Medicinal Chemistry, Vrije University, The Netherlands

GPCR-Targeted Antibodies in Hypertensive Diseases

Meredith Skiba, PhD, Postdoctoral Fellow, Biological Chemistry, Harvard Medical School

Specificity Screening of Antibodies and Related Molecules Using Human Cell Microarray Technology

Jim Freeth, PhD, Co-Managing Director, Retrogenix Limited, United Kingdom

Presentation to be Announced

ION CHANNEL TARGETS

Engineering of Tarantula Venom Peptides to Inhibit the Human Voltage-Gated Sodium Channel hNav1.7

Robert Neff, PhD, Senior Scientist, Janssen

Novel Binding Strategies for Sodium Channel Targets

Bonnie Ann Wallace, PhD, Professor, Institute of Structural and Molecular Biology, Birkbeck College, United Kingdom

TRP Channel Agonists Reveal Ligand-Binding and Modality-Specific Pain Mechanisms

Jun Chen, PhD, Senior Scientist, Genentech

Antisense Oligonucleotides Targeting Ion Channels for Pain

Owen McManus, PhD, Chief Technology Officer, Q-State Bioscience

SPECIAL PRESENTATION

Pipeline Update: GPCR and Ion Channel Antibodies

Catherine Hutchings, PhD, Independent Consultant, United Kingdom

TRANSPORTER TARGETS

The Molecular Architecture of GABAergic Synapses

Joshua Smalley, PhD, Postdoctoral Scholar, Tufts University

Role of Plasmodium falciparum Chloroquine Resistance Transporter in Anti-Malarial Drug Resistance

Jonathan Kim, PhD, Postdoctoral Researcher, Physiology & Cellular Biophysics, Columbia University


Please click here to continue to the agenda for Antibodies Against Membrane Protein Targets – Part 2



For more details on the conference, please contact:
Kent Simmons

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 207-869-9199
Email: ksimmons@healthtech.com

 

For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com